若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

Trolox

维生素E类似物

产品号 #(选择产品)

产品号 #100-0572_C

维生素E类似物

总览

Trolox是一种细胞渗透性、亲水的维生素E类似物(Choe et al.;Lee et al.)。在小鼠中,Trolox已被证明通过下调NF-κB受体活化因子配体(RANKL)诱导和c-Fos表达来抑制破骨细胞形成(Lee et al.)。Trolox还能阻止顺铂诱导的肾上皮细胞凋亡(Xiao et al.)。

分化
·诱导人胚胎干细胞向β样细胞分化(Petersen et al.)。
癌症研究
·增强骨髓瘤和乳腺癌细胞中砷介导的细胞凋亡(Diaz et al.)。

别名
6-羟基-2,5,7,8-四甲基色烷-2-羧酸
 
细胞类型
癌细胞及细胞系,胰腺细胞
 
应用
分化
 
研究领域
癌症,干细胞生物学
 
CAS 编号
53188-07-1
 
化学式
C14H18O4
 
分子量
250.3 克/摩尔
 
纯度
≥98%
 
通路
WNT
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
Trolox
Catalog #
100-0572, 100-0573
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Trolox
Catalog #
100-0572, 100-0573
Lot #
All
Language
English

相关材料与文献

技术资料 (4)

文献 (5)

Trolox-induced cardiac differentiation is mediated by the inhibition of Wnt/$\beta$-catenin signaling in human embryonic stem cells. M. S. Choe et al. Cell biology international 2019 jul

Abstract

Cardiac differentiation of human pluripotent stem cells may be induced under chemically defined conditions, wherein the regulation of Wnt/$\beta$-catenin pathway is often desirable. Here, we examined the effect of trolox, a vitamin E analog, on the cardiac differentiation of human embryonic stem cells (hESCs). 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox) significantly enhanced cardiac differentiation in a time- and dose-dependent manner after the mesodermal differentiation of hESCs. Trolox promoted hESC cardiac differentiation through its inhibitory activity against the Wnt/$\beta$-catenin pathway. This study demonstrates an efficient cardiac differentiation method and reveals a novel Wnt/$\beta$-catenin regulator.
Single-Cell Gene Expression Analysis of a Human ESC Model of Pancreatic Endocrine Development Reveals Different Paths to $\beta$-Cell Differentiation. M. B. K. Petersen et al. Stem cell reports 2017

Abstract

The production of insulin-producing $\beta$ cells from human embryonic stem cells (hESCs) in vitro represents a promising strategy for a cell-based therapy for type 1 diabetes mellitus. To explore the cellular heterogeneity and temporal progression of endocrine progenitors and their progeny, we performed single-cell qPCR on more than 500 cells across several stages of in vitro differentiation of hESCs and compared them with human islets. We reveal distinct subpopulations along the endocrine differentiation path and an early lineage bifurcation toward either polyhormonal cells or $\beta$-like cells. We uncover several similarities and differences with mouse development and reveal that cells can take multiple paths to the same differentiation state, a principle that could be relevant to other systems. Notably, activation of the key $\beta$-cell transcription factor NKX6.1 can be initiated before or after endocrine commitment. The single-cell temporal resolution we provide can be used to improve the production of functional $\beta$ cells.
Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J.-H. Lee et al. The Journal of biological chemistry 2009 may

Abstract

Excessive receptor activator of NF-kappaB ligand (RANKL) signaling causes enhanced osteoclast formation and bone resorption. Thus, down-regulation of RANKL expression or its downstream signals may be a therapeutic approach to the treatment of pathological bone loss. In this study, we investigated the effects of Trolox, a water-soluble vitamin E analogue, on osteoclastogenesis and RANKL signaling. Trolox potently inhibited interleukin-1-induced osteoclast formation in bone marrow cell-osteoblast coculture by abrogating RANKL induction in osteoblasts. This RANKL reduction was attributed to the reduced production of prostaglandin E(2) via a down-regulation of cyclooxygenase-2 activity. We also found that Trolox inhibited osteoclast formation from bone marrow macrophages induced by macrophage colony-stimulating factor plus RANKL in a reversible manner. Trolox was effective only when present during the early stage of culture, which implies that it targets early osteoclast precursors. Pretreatment with Trolox did not affect RANKL-induced early signaling pathways, including MAPKs, NF-kappaB, and Akt. We found that Trolox down-regulated the induction by RANKL of c-Fos protein by suppressing its translation. Ectopic overexpression of c-Fos rescued the inhibition of osteoclastogenesis by Trolox in bone marrow macrophages. Trolox also suppressed interleukin-1-induced osteoclast formation and bone loss in mouse calvarial bone. Taken together, our findings indicate that Trolox prevents osteoclast formation and bone loss by inhibiting both RANKL induction in osteoblasts and c-Fos expression in osteoclast precursors.

更多信息

更多信息
Molecular Weight 250.3 g/mol
Alternative Names 6-Hydroxy-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid
Cas Number 53188-07-1
Chemical Formula C14H18O4
纯度 ≥ 98%
Pathway WNT
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.